To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. If you experience any issues with your products or services, please contact ATCC Customer Service at sales@atcc.org. For Technical questions please contact tech@atcc.org. Thank you.
X
Search

NK-92® MI (ATCC® CRL-2408™)

Organism: Homo sapiens, human  /  Cell Type: natural killer cell; NK cell  /  Tissue: peripheral blood, blood  /  Disease: malignant non-Hodgkin's lymphoma

Permits and Restrictions

View Permits View Restrictions
Organism Homo sapiens, human
Tissue peripheral blood, blood
Cell Type natural killer cell; NK cell
Product Format frozen
Morphology lymphoblast
Culture Properties suspension, multicell aggregates
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease malignant non-Hodgkin's lymphoma
Age 50 years
Gender male
Ethnicity Caucasian
Applications
The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays.
Storage Conditions liquid nitrogen vapor phase
Images ATCC CRL-2408 Micrograph
Derivation
NK-92® MI is an interleukin-2 (IL-2) independent Natural Killer Cell line derived from the NK-92® (ATCC CRL-2407) cell line by transfection. NK-92® is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma. The parental cells were transfected with human IL-2 cDNA in the retroviral MFG-hIL-2 vector by particle-mediated gene transfer. The transfection is stable.
Clinical Data
male
50 years
Caucasian
Comments
NK-92® and this derivative cell line NK-92® MI have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR. 

The parental IL-2 dependent cell line is available as ATCC CRL-2407 (NK-92® ). NK-92® MI was shown to contain, express, and synthesize the hIL-2.

A culture submitted to the ATCC in September of 1998 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline. The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative.

ATCC confirmed this cell line is positive for the presence of Epstein-Barr viral DNA sequences via PCR.
Complete Growth Medium The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; horse serum to a final concentration of 12.5%; fetal bovine serum to a final concentration of 12.5%.
Subculturing

Cultures can be maintained by centrifuging cells and resuspending cell pellet in fresh medium at 2 - 3 x 105 viable cells/mL. Centrifugation and full replacement of culture medium may be performed for the first subcultures. Cultures can then be maintained by addition of fresh medium. These cells tend to grow in aggregates that may lose viability when they are dispersed. Accurate counts and viabilities may not be possible.

Maintain cell density between 2 x 105 and 1 x 106 viable cells/mL or use a 1:3 spilt ratio.
Cryopreservation
Freeze medium: FBS, 90%; DMSO, 10%
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile
D5S818: 12. 13
D13S317: 9, 12
D7S820: 10, 11
D16S539: 11, 12
vWA: 16, 18
TH01: 6, 9.3
TPOX: 8
CSF1PO: 11, 12
Amelogenin: X, Y
Name of Depositor NantKwest Inc.
Deposited As human
Year of Origin 1998
References

Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260

Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666

Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • For-profit customers must obtain a research use license agreement from the Contributor prior to shipment.
  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
Other Documentation
Other Document
Cell Micrograph
Restrictions

The NK-92® cell line was deposited at the ATCC by NantKwest Inc. and is available with the following restrictions:

  1. Not-for-profit academic institutions may use this cell line for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes, including but not limited to the testing or validation of any commercial product or instrument. Nor can the cells be distributed to third parties for any reason, including purposes of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied.
  2. For-profit commercial organizations must obtain a research use and/or a commercial license directly from NantKwest Inc. For instructions on how to proceed, please contact NantKwest’s licensing department via email at contact@nantkwest.com.
NK-92® is a registered trademark of Nantkwest, Inc.
References

Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260

Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666

Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052